Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors

Chemico-Biological Interactions

Volumn 142, Issue 1-2, 2002, Pages 57-71

  Lloyd, Scott ^a   Hayden, Michael J ^a   Sakai, Yumiko ^a   Fackett, Andrew ^a   Silber, Paul M ^a   Hewitt, Nicola J ^a   Li, Albert P ^a  

^a In Vitro Technologies Inc   (United States)

Author keywords

Adenosine triphosphate; Hepatocytes; Troglitazone

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOSINE TRIPHOSPHATE; GLUTATHIONE; NEUTRAL RED; ROSIGLITAZONE; TROGLITAZONE;

ADOLESCENT; ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CELL LEVEL; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYOPRESERVATION; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL; LIVER TOXICITY; MALE; PRESCHOOL CHILD; SEX DIFFERENCE; SMOKING;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; CHROMANS; COLORING AGENTS; FEMALE; FORMAZANS; GLUTATHIONE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; LIVER DISEASES; MALE; MIDDLE AGED; NEUTRAL RED; OXAZINES; SEX FACTORS; SMOKING; TETRAZOLIUM SALTS; THIAZOLES; THIAZOLIDINEDIONES; XANTHENES;

NICOTIANA TABACUM;

EID: 0037058254     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(02)00054-6     Document Type: Article

References (16)

1. Brown D.L., Brillon D. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy. J. Natl. Med. Assoc. 91:(7):1999;389-395.
2. Kausch C., Krutzfeldt J., Witke A., Rettig A., Bachmann O., Rett K., Matthaei S., Machicai F., Haring H.U., Stumvoll M. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem. Biophys. Res. Com. 280:2001;664-674.
3. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
4. Spiegelman B.M. Perspectives in diabetes. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514.
5. Biswas P., Wilton L.V., Shakir S.A. Troglitazone and liver function abnormalities. Drug Saf. 24:(2):2001;149-154.
6. Donnelly R. FDA Reviews Troglitazone. Diab. Obes. Metab. 1:1999;65-66.
7. CSM/MCA, Troglitazone (Romozin) withdrawn, Curr. Probl. Pharmacovigil 23 (1997) 12.
8. Scheen A.J. Thiazolidinediones and liver toxicity. Diabetes Metab. 27:(3):2001;305-313.
9. Forman L.M., Simmons D.A., Diamond R.H. Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. 132:2000;118-121.
10. Al-Salman J., Arjomand H., et al. Hepatocellular injury in a patient receiving rosiglitazone. Ann. Intern. Med. 132:2000;121-124.
11. Toyoda Y., Tsuchida A., Iwami E., Miwa I. Toxic effect of troglitazone on cultured rat hepatocytes (2001). Life Sci. 68:2001;1867-1876.
12. Funk C., Ponelle C., Scheuermann G., Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity; in vivo and in vitro interaction at the canalicular bile salt export pump (bsep) in the rat. Mol. Pharmacol. 59:2001;627-635.
13. Loretz L.J., Li A.P., Flye M.W., Wilson A.G.E. Optimization of cryopreservation procedures for rat and human hepatocytes. Xenobiotica. 19:1989;489-498.
14. Li A.P., Roque M.A., Beck D.J., Kaminski D.L. Isolation and culturing of hepatocytes from human livers. J. Tiss. Cult. Meth. 14:1992;139-146.
15. Li A.P., Lu C., Brendt J.A., Pham C., Fackett A., Ruegg C.E., Silber P.A. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121:1999;17-35.
16. Senft A.P., Dalton T.P., Shertzer H.G. Determining glutathione and glutathione disulfide using the fluorescence probe o-pthaldehyde. Anal. Biochem. 280:(1):2000;80-86.